Latisse gains popularity among those seeking longer, fuller lashes
St. Louis — As women become more familiar and comfortable with the idea of a medication that can help give them the kind of lush, long eyelashes they’ve always wanted, physicians have increasingly found themselves prescribing Latisse (bimatoprost ophthalmic solution 0.03 percent, Allergan) and addressing eyelash issues previously dealt with primarily at the cosmetics counter. (Source: Modern Medicine)
Read the rest here:
Latisse gains popularity among those seeking longer, fuller lashes
Glaucoma eye drops drug Latisse used OTC to make long eyelashes but some now face side effects
From the NYTimes:Latisse is the same formula as Lumigan, Allergan’s eyedrops for glaucoma, which reduces eye pressure but also happens to grow lashes. Both are also known as bimatoprost ophthalmic solution.
Go here to read the rest:
Glaucoma eye drops drug Latisse used OTC to make long eyelashes but some now face side effects
Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)
See original here:
Latisse Faces Patent Challenge
From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth
Dr. Cohen has been a consultant and clinical trial investigator for Allergan (including related to Latisse).
Read the original:
From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth
Policy & Practice
Can’t get enough Policy & Practice? Check out our new podcast each Monday
See the rest here:
Policy & Practice
FDA: Allergan’s Web Site Is Misleading
The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven. (Source: WSJ.com: Health)
Read more:
FDA: Allergan’s Web Site Is Misleading
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
Allergan Gets Nod For Eyelash Treatment
Eye care and cosmetic drug maker Allergan on Friday said its eyelash growth treatment Latisse received Food and Drug Administration approval,… (Source: Investor’s Business Daily: HEALTH)
See the original post here:
Allergan Gets Nod For Eyelash Treatment
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse…
Epione Beverly Hills- Revolutionary New Sunblock Formula ‘Protects and Corrects’
- Epione Beverly Hills Helps Kick Off 2010 Teen Choice Awards’ Festivities with KIIS FM
- Beverly Hills Leader in Cosmetic Procedures Earns Allergan’s Highest Level of Recognition
- Dr. Simon Ourian to Offer Industry Expertise to Medicis
- The Cast of ‘Jersey Shore’ Learns Safe Tanning Tips and Secrets from Epione Beverly Hills
- Image is Everything: Three Aesthetic Treatments for Building Confidence and Looking and Feeling Your Best
- Why More Women are Choosing OptiLipo over Liposuction
- Say “Adios” to Acne Scars
- New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates’ Number One Concern: Recovery Time
- Epione Reveals a “Bright” New Solution for Dull, Sun Damaged Skin